Enhanced sequencing capabilities offer opportunity to accelerate breakthroughs in life science research SAN JOSE, Calif., Dec. 29, 2022 /PRNewswire/ — Complete Genomics Inc（https://completegenomics.mgiamericas.com/）, a subsidiary of MGI Tech Co., Ltd…. […]
– Patent covers more than 100 novel compounds targeting neurodegenerative diseases including Parkinson’s and Alzheimer’s – MELBOURNE, Australia and SAN FRANCISCO, Dec. 29, 2022 /PRNewswire/ — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” … […]
EMERYVILLE, Calif., Dec. 29, 2022 /PRNewswire/ — Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world’s transition to sustainable consumption through its Lab-to-Market™ technology platform, today announced that… […]
LANSING, Mich., Dec. 29, 2022 /PRNewswire/ — Neogen Corporation (NASDAQ: NEOG) announced today that the Company will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 11, 2023. John Ad… […]
MENLO PARK, Calif., Dec. 28, 2022 /PRNewswire/ — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the following events at the 41st Annual J.P. Morgan Hea… […]
PLEASANTON, Calif., Dec. 28, 2022 /PRNewswire/ — 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be participating in the upcoming 41st Annual J.P. Morgan H… […]
SAN FRANCISCO, Dec. 28, 2022 /PRNewswire/ — If you purchased Atripla®, Biktarvy®, Complera®, Descovy®, Evotaz®, Genvoya®, Odefsey®, Prezcobix®, Stribild®, Symtuza®, Truvada®, or Viread®, a class action lawsuit may affect your rights. If you are a memb… […]
The companies will begin with a collaboration to improve single-cell analytics for hematologic cancers SOUTH SAN FRANCISCO, Calif., Dec. 28, 2022 /PRNewswire/ — Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, and … […]
Gilead Sciences has bought out Jounce Therapeutics’ anti-CCR8 antibody for $67 million, taking over full R&D and commercial rights to the experimental cancer immunotherapy drug. The deal will give Jounce enough cash to keep operating into the third… […]
SAN DIEGO–(BUSINESS WIRE)–Boundless Bio. a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Executive Officer, Za… […]
Copyright © 2022 Biotech Networks, LLC
